
Claims

1. Use of a compound having the general formula Ia:



wherein
m is 0, 1, 2, 3 or 4;
n is 0, 1, 2, or 3;
X, Y and Z are CH;

R^1 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C_1-C_{10} alkyl, C_1-C_3 haloalkyl, C_3-C_7 cycloalkyl, hydroxyl, oxo, -OR^4, -$C(O)OR^4$, -$C(O)R^4$, -$C(O)N(R^4)_2$, -CN, -NO_2, -NH_2, -$N(R^4)_2$, -OR^4HetA, -$OR^4N(R^4)_2$, -$C(O)N(R^4)R^4$HetA, -$C(O)N(R^4)$HetA, -C(O)HetA, -$C(O)N(R^4)R^4S(O)_2R_4$; -$S(O)_2N(R^4)_2$, -$S(O)_2R^4$, -$N(R^4)C(O)R^4SR^4$, -$N(R^4)R^4S(O)_2R^4$, -$N(R^4)S(O)_2R^4$, -$C(S)R^4$, aryl, benzyl, and heterocyclyl;

R^2 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_{10} haloalkyl, -OH, -OR^5, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkoxy, C_3-C_{15} cycloalkylalkoxy, C_3-C_{15} cycloalkylalkyl, -CN, -NO_2, -NH_2, -$N(R^5)_2$, -$C(O)R^5$, -$C(O)OR^5$, -$C(O)N(R^5)_2$, -SR^5, -$S(O)R^5$, -$S(O)_2R^5$, -$S(O)_2N(R^5)_2$, aryl, benzyl, heteroaryl, and heterocyclyl;

R^3 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, hydroxyl, -OR^6, -CN, -NO_2, -NH_2, -$N(R^6)C(O)R^6$, -$C(O)R^6$, -$C(O)OR^6$, -$C(O)N(R^6)_2$, -$S(O)R^6$, -$S(O)_2R^6$, -$S(O)_2N(R^6)_2$, aryl, benzyl, heteroaryl, heterocyclyl, or two groups of R^3 are connected to each other to make a five or six membered cyclic or heterocyclic rings;


R^4 is, at each occurrence, independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_{10} haloalkyl, $-C(O)R^7$, $-R^7(R^7)C(O)R^7$, $-C(O)OR^7$, $-R^7(R^7)C(O)OR^7$, $-C(O)N(R^7)_2$, $-R^7(R^7)C(O)N(R^7)_2$, $-S(O)R^7$, $-S(O)_2R^7$, $-S(O)_2N(R^7)_2$, aryl, benzyl, heteroaryl, and heterocyclyl;

R^5, R^6 and R^7 are, at each occurrence, independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_{10} haloalkyl, aryl, benzyl, heteroaryl, and heterocyclyl; and


pharmaceutically acceptable salts thereof, and

wherein the compound has a formula selected from the following formulae 5, 8, 13, 14, 17, 18, 20, 21, 23-43, 46, 48, 50, 51, 53, 59, 68, 69, 74, 79, 80, 89-91, 142, 143, 161, 196, 211-213, 219, 221, 222, 239-247, 264, 313-329 and 331:


2-Methyl-N-(pyridin-4-yl)imidazo[1,2-a]pyridine-3-carboxamide (5)




N-Benzyl-2-methylimidazo[1,2-a]pyridine-3-carboxamide (8)




2-Methyl-N-(pyridin-3-ylmethyl)imidazo[1,2-a]pyridine-3-carboxamide (13)



2-Methyl-N-(pyridin-4-ylmethyl)imidazo[1,2-a]pyridine-3-carboxamide (14)




2-Ethyl-7-(4-(4-fluorobenzyl)piperazin-1-yl)-*N*-(4-morpholinobenzyl)imidazo[1,2-a]pyridine-3-carboxamide (331)



in the manufacture of a medicament for the treatment of a bacterial infection.

2. The use according to claim 1, for the treatment of tuberculosis.

3. Use of a compound having the general formula Ib:



Ib

wherein
o is 0, 1, 2, or 3;
n is 0;
m is 1, 2, 3 or 4;
X, Y and Z are CH;

A is C=O or C=S


W is NR^{11};

R^2 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl,
C_1-C_{10} haloalkyl, -OH, $-OR^5$, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkoxy, C_3-C_{15} cycloalkylalkoxy, C_3-C_{15} cycloalkylalkyl, -CN, $-NO_2$, $-NH_2$, $-N(R^5)_2$, $-C(O)R^5$, $-C(O)OR^5$, $-C(O)N(R^5)_2$, $-SR^5$, $-S(O)R^5$, $-S(O)_2R^5$, $-S(O)_2N(R^5)_2$, aryl, benzyl, and heterocyclyl;

R^3 is, at each occurrence, independently selected from the group consisting of hydrogen, halogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, hydroxyl, $-OR^6$, -CN, $-NO_2$, $-NH_2$, $-N(R^6)C(O)R^6$, $-C(O)R^6$, $-C(O)OR^6$, $-C(O)N(R^6)_2$, $-S(O)R^6$, $-S(O)_2R^6$, $-S(O)_2N(R^6)_2$, aryl, benzyl, heteroaryl, heterocyclyl, or two groups of R^3 are connected to each other to make a five or six membered cyclic or heterocyclic rings;

R^5 and R^6 are, at each occurrence, independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_{10} haloalkyl, aryl, benzyl, heteroaryl, and heterocyclyl;

R^{10} is a moiety selected from the group consisting of



R^{11} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_{10} haloalkyl, -OH, -OR^{13}, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkoxy, C_3-C_{15} cycloalkylalkoxy, C_3-C_{15} cycloalkylalkyl, -NH_2, -$N(R^{13})_2$, -$C(O)R^{13}$, -$C(O)OR^{13}$, -$C(O)N(R^{13})_2$, -$S(O)R^{13}$, -$S(O)_2R^{13}$, -$S(O)_2N(R^{13})_2$, aryl, benzyl, heteroaryl, and heterocyclyl;

R^{12} is, at each occurrence, independently selected from the group consisting of C_2-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_{10} haloalkyl, hydroxyl, $-OR^{14}$, $-C(O)R^{14}$, $-C(O)OR^{14}$, -CN, $-NO_2$, $-NH_2$, $-N(R^{14})_2$, $-C(O)N(R^{14})_2$, $-S(O)R^{14}$, $-S(O)_2R^{14}$, $-S(O)_2N(R^{14})_2$, aryl, benzyl, heteroaryl, and heterocyclyl;

R^{13} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_{10} haloalkyl, aryl, benzyl, heteroaryl, and heterocyclyl; and

R^{14} is, at each occurrence, independently selected from the group consisting of hydrogen, C_1-C_8 alkyl optionally substituted with at least one hydroxyl or halogen; C_3-C_7 cycloalkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkenyl, C_2-C_{10} alkynyl, C_1-C_{10} haloalkyl, aryl, benzyl, heteroaryl and heterocyclyl;

and pharmaceutically acceptable salts thereof in the manufacture of a medicament for the treatment of a bacterial infection.

4. The use according to claim 3, for the treatment of tuberculosis.